These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9768820)

  • 1. Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.
    Imondi AR
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):22-30. PubMed ID: 9768820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
    Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
    Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.
    de Beer EL; Bottone AE; van Rijk MC; van der Velden J; Voest EE
    Br J Pharmacol; 2002 Apr; 135(7):1707-14. PubMed ID: 11934811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
    Herman EH; Ferrans VJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):15-21. PubMed ID: 9768819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.
    Synold TW; Tetef ML; Doroshow JH
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):93-9. PubMed ID: 9768830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice.
    Saadane N; Yue P; Alpert L; Mitmaker B; Kirby GM; Chalifour LE
    Can J Physiol Pharmacol; 2001 Jun; 79(6):533-44. PubMed ID: 11430591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel.
    Della Torre P; Imondi AR; Bernardi C; Podestà A; Moneta D; Riflettuto M; Mazué G
    Cancer Chemother Pharmacol; 1999; 44(2):138-42. PubMed ID: 10412948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
    Yoshida M; Maehara Y; Sugimachi K
    Clin Cancer Res; 1999 Dec; 5(12):4295-300. PubMed ID: 10632373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M; Vici P
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexrazoxane's protection of jejunal crypt cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicity.
    Pearlman M; Jendiroba D; Pagliaro L; Keyhani A; Liu B; Freireich EJ; Travis E
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):477-81. PubMed ID: 12827292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
    Bjelogrlic SK; Radic J; Radulovic S; Jokanovic M; Jovic V
    Exp Biol Med (Maywood); 2007 Dec; 232(11):1414-24. PubMed ID: 18040065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
    Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
    Sparano JA
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane.
    Della Torre P; Mazué G; Podestà A; Moneta D; Sammartini U; Imondi AR
    Cancer Chemother Pharmacol; 1999; 43(2):151-6. PubMed ID: 9923821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
    Robert J
    Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
    Mladosievicova B; Foltinová A; Petrásová H; Bernadic M; Hulín I
    Neoplasma; 2001; 48(1):61-5. PubMed ID: 11327539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac response to doxorubicin and dexrazoxane in intact and ovariectomized young female rats at rest and after swim training.
    Calvé A; Haddad R; Barama SN; Meilleur M; Sebag IA; Chalifour LE
    Am J Physiol Heart Circ Physiol; 2012 May; 302(10):H2048-57. PubMed ID: 22447943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
    Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
    Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.